SEMIFIVE IPO Targets Global AI ASIC Market with 3D-IC, Large-Die Designs
December 17, 2025, 2:21 AM EST. SEMIFIVE is accelerating its global push in the AI ASIC market through an IPO, aiming to lead next-gen technologies such as 3D-IC and large-die designs while expanding across the US, China, Japan, Europe and India. The company blends development services, mass production supply and IP revenue into a recurring model, backed by turnkey engineering from specification to mass production. New orders surged to KRW 123.9 billion in 2024 from KRW 57.2 billion in 2022, with profitability expected to rise as projects move from development to mass production in H2. At its Dec 17 press conference, SEMIFIVE highlighted platformizing semiconductor design to lower entry barriers, akin to TSMC's platformization. Partnerships with Hanwha Vision, a global NAND company, Furiosa AI, Rebellions and HyperAccel reinforce its fabless ecosystem.
SEMIFIVE Aims Global AI ASIC Leadership Through IPO With 3D-IC, Large-Die and Platform-Based Design
December 17, 2025, 2:20 AM EST. SEMIFIVE, a Seoul-based provider of custom AI ASIC design, is pursuing an IPO to scale its platformized approach to chips. With orders rising from KRW 57.2 billion in 2022 to KRW 123.9 billion in 2024, the company cites a shift toward AI ASICs and a high-performance, scalable design platform as growth engines. The IPO subscription is December 18-19, with listing expected later this year. Management envisions leadership in next-generation technologies such as 3D-IC and large-die designs, expanding across the United States, China, Japan, Europe and India. SEMIFIVE offers end-to-end services from specification to mass production, generating recurring revenue through development, production, and IP. Partners include Hanwha Vision and AI fabless firms such as Furiosa AI, Rebellions, and HyperAccel, underscoring a global, turnkey supply footprint.
Keppel Ltd: Data Centre Asset Recycling Signals Shift to Higher-Quality Cash Flows
December 17, 2025, 2:19 AM EST. Keppel Ltd (SGX: BN4) reinforced its asset-light strategy on 17 Dec 2025 by selling the remaining 10% of Keppel DC Singapore 3 and 1% of Keppel DC Singapore 4 to Keppel DC REIT for S$50.5 million, with completion expected by 1Q2026. The move underlines ongoing capital recycling-turning mature assets into deployable capital to fund higher-return, fee-generating growth-and supports the board's aim of shareholder value via buybacks. Management flags this as part of a broader monetisation programme, lifting year-to-date proceeds above S$2.4 billion and helping to clean up the balance sheet. Near-term NTA/EPS impact is modest. The assets are Tampines-based carrier-neutral data centres (~139,469 sq ft) with tenants of solid credit profiles, reinforcing a digital infrastructure exposure and a more predictable cash flow.
Greencore Group plc (LON:GNC) Could Be ~49% Undervalued, Says DCF Valuation
December 17, 2025, 2:18 AM EST. Greencore Group plc (LON:GNC) appears potentially undervalued after a DCF-based intrinsic value estimate of UK£4.89 versus a UK£2.49 share price. The analysis implies ~49% upside to fair value. Using a 2-stage growth model, the forecast covers ten years of levered FCF (e.g., £108.7m in 2026, tapering to £109.4m by 2035) with the first stage set by analyst estimates and adjustments. The ten-year PV of cash flows adds up to about £720m (PVCF). The Terminal Value uses Gordon Growth at a 3.0% long-run growth rate, discounted at the cost of equity of 7.1%, yielding the bulk of value today. While DCF is not perfect, this framework suggests the market price may not fully reflect the company's cash-generative potential.
Keppel Ltd (SGX:BN4) Data-Centre Divestment, Buybacks, and Analyst Outlook
December 17, 2025, 2:17 AM EST. Keppel Ltd (SGX:BN4) is back in focus as it pursues an asset-light playbook: recycling capital, monetising mature assets, and supporting shareholder returns through buybacks. The focus is on repeatable moves that could lift Keppel toward a higher-quality, fee-earning asset manager with a cleaner balance sheet and more predictable cash flows. The latest catalyst: Keppel's Connectivity Division sells its remaining 10% stake in KDC SGP 3 and 1% in KDC SGP 4 to Keppel DC REIT for S$50.5m, with completion expected in 1Q 2026. It signals discipline and capital recycling rather than an immediate earnings uplift. Monetisation year-to-date surpasses S$2.4b, underscoring the strategy to turn assets into deployable capital for higher-return bets, notably its growing digital infrastructure exposure. The divestment is not expected to materially affect current-year NTA or EPS, reinforcing that the move is balance-sheet and strategy execution, not a quarterly earnings surprise.
Greencore Group plc (LON:GNC) Could Be 49% Undervalued Based on DCF Valuation
December 17, 2025, 2:16 AM EST. Greencore Group plc (LON:GNC) appears to be trading at a substantial discount to its estimated intrinsic value. Using a 2-stage DCF to equity, the analysis puts a fair value of about UK£4.89 per share, compared with the December price of UK£2.49 – implying the stock could be ~49% undervalued. The model projects levered FCF reaching £108.7m in 2026 and a rising path through 2035, with a discount rate of 7.1%. The present value of the 10-year cash flows (PVCF) totals roughly £720m, while the terminal value is calculated using Gordon Growth at the 5-year average government bond yield (~3.0%). The article notes peers trade with different discounts, and that a DCF is one of several methods to estimate value.
Greencore Group plc (LON:GNC) Could Be 49% Undervalued Based on DCF Valuation
December 17, 2025, 2:15 AM EST. Using a two-stage DCF, Simply Wall St estimates Greencore Group's fair value at UK£4.89, vs a current price of UK£2.49, implying about a 49% undervaluation. The analysis notes the stock's intrinsic value relies on projected cash flows, a two-stage growth model, and a discount rate of 7.1%. The 10-year levered FCF schedule shows modest growth, with a Terminal Value guided by a 3.0% long-term growth assumption. While forecasts depend on estimates, the calculation highlights the stock as potentially undervalued relative to peers and its fair value as a multiple of FCF.
UOB (SGX: U11) Outlook Dec 17, 2025: Greater China Property Exposure, Provisions and Dividend Path
December 17, 2025, 2:14 AM EST. UOB shares (SGX: U11) were in focus on Dec 17, 2025 as investors weigh its exposure to Hong Kong and mainland China real estate after a sizable pre-emptive provisioning. The key questions: can UOB's clean-up provisions cover potential losses, is Greater China asset quality stress containable, and will dividends and buybacks stay durable amid NIM pressure into 2026. Reports show UOB's substantial historical lending to property in Greater China, including CRE development and investment loans. The bank booked about S$615 million in CRE provisions, lifting allowances to S$1.9 billion for 9M25. Hong Kong unit's property lending stood at HK$69.2 billion (43% of the unit's gross loans) as of June 2025. The debate: is the China/property risk a contained leak or a longer-term challenge?
UOB Stock Outlook (SGX: U11) Dec 17, 2025: China Property Exposure, Dividends, and Analyst Targets
December 17, 2025, 2:13 AM EST. UOB is back in focus as investors weigh its exposure to Hong Kong and China real estate and whether its provisions suffice as Greater China stress persists. The stock (SGX: U11) traded around S$34.61 on Dec 17, down 0.4%, with a 52-week range of S$29.00-S$39.20. The big questions: can UOB's clean-up provisions absorb ongoing risk, is asset quality in Greater China manageable, and can dividends and buybacks stay durable as net interest margins compress into 2026? Recent reporting shows UOB booked S$615m in CRE provisions, lifting allowances to S$1.9b for the first nine months of 2025. In Greater China, loans total S$48b with a NPL ratio of 3.1% vs the group's 1.6%. The backdrop remains ongoing China property stress.
UOB Stock (SGX: U11) Outlook on Dec 17, 2025: China Property Exposure, Dividends & Analyst Targets
December 17, 2025, 2:12 AM EST. UOB's stock remains in the spotlight as it weighs its exposure to Hong Kong and mainland China property and the durability of shareholder returns. The bank booked S$615 million in general provisions for CRE risk, lifting allowances to S$1.9 billion for 9M 2025, even as its overall NPL ratio stays modest. Hong Kong's branch carries a large share of property development/investment loans (HK$69.2B, ~43% of its gross loans as of mid-2025), underscoring sensitivity to a stretched property cycle. Market focus centers on whether asset quality stress remains containable, whether dividends and buybacks can stay resilient as net interest margins compress into 2026, and how the bank's Greater China loan book translates into risk versus peer banks. Ongoing reports on China property liquidity add to the uncertainty.
Keppel Ltd Stock (SGX: BN4) Today: Data Centre Divestment, Buybacks, and Analyst Outlook
December 17, 2025, 2:10 AM EST. Keppel Ltd (SGX: BN4) sharpens its asset-light, capital recycling narrative as it sells the remaining 10% stake in KDC SGP 3 and 1% in KDC SGP 4 to Keppel DC REIT for S$50.5 million, with completion expected in 1Q 2026. The move signals ongoing monetisation rather than an earnings surprise, aligning with a strategy to convert mature assets into deployable capital for higher-return ventures and predictable cash flows. Management frames this as part of a broader monetisation run-rate, now above S$2.4 billion year-to-date, and a tilt toward digital infrastructure (data centres, subsea cables) as a growth engine. Analysts' targets imply upside potential but near-term EPS impact is limited; the focus remains on balance-sheet strength, buybacks, and a higher-quality, fee-earning profile.
ST Engineering Stock (SGX:S63) Near S$8.23 as Electric Bus Win Shapes Outlook
December 17, 2025, 2:02 AM EST. ST Engineering shares traded around S$8.23 on Dec 17, 2025, as investors weigh a fresh public-transport contract against aerospace headlines. The stock faces a classic two-engine thesis: a growing mobility/defence-adjacent pipeline that boosts revenue visibility and shareholder returns, versus risk pockets in US aviation MRO and satellite-communications restructuring. A near-term catalyst is a Singapore LTA award for about S$114.7 million in electric buses to ST Engineering Mobility Services (CRRC partnership), strengthening public-sector order flow and the group's smart-mobility footprint. Valuation remains firm: market cap around S$25.8 billion, P/E (TTM) ~33.6, and a trailing dividend yield around 2.06%. The stock sits below its 52-week high of S$9.07 but well above the 52-week low near S$4.50, signaling renewed rerating despite aerospace risks.
Singapore Exchange Ltd (SGX: S68) Stock Outlook: November Turnover Surge, Nasdaq Dual-Listing Bridge, Analyst Targets
December 17, 2025, 2:01 AM EST. SGX sits as a picks-and-shovels play on markets, benefiting when activity rises across cash equities, derivatives, FX and commodities. November trading activity came in robust, with turnover value up 18% YoY to S$35.5 billion and SDAV up 24% to S$1.8 billion, signaling stronger momentum for the stock. The Straits Times Index rose, aiding sentiment, as SGX's revenue remains tied to transaction flow and product mix. Beyond equities, SGX continues to build a multi-asset platform, expanding into commodities and crypto. With policy efforts to reboot Singapore's equity market and potential Nasdaq tie-ins, investors will watch if the momentum sustains into 2026.
Barclays: Bank of Mum and Dad fuels second-time buyers with avg £81,451
December 17, 2025, 1:58 AM EST. Barclays' latest property insights reveal the Bank of Mum and Dad remains pivotal for Britain's housing ladder. Among second-steppers who received financial help, the average support was £81,451, while 20% benefited from family or friends. By contrast, 30% of first-time buyers got help, averaging £76,239. About 49% of owners who benefited for a second or third home also received help for their first purchase. The most common forms are lump-sum gifts from parents (39%), inheritance (27%) and loans (13%). For renters, 52% say an inheritance or loan would be essential to buy. Jatin Patel says the market is in transition amid affordability pressures, with more renters able to access finance despite ongoing price hurdles.
SBI Holdings (TSE:8473) Valuation Revisited After Recent Pullback
December 17, 2025, 1:57 AM EST. SBI Holdings (TSE:8473) has seen a ~7% pullback over the last month but remains up strongly year to date, setting up a fresh valuation check. The stock trades near analyst targets but well below some intrinsic values, with a fair value of ¥3,323 implying only a slim upside from the latest close of ¥3,315. Growth bets hinge on aggressive expansion into digital assets, stablecoins, blockchain, and AI, supported by robust segment profits and tech alliances. Yet regulatory scrutiny and uncertain legislative frameworks ahead could raise compliance costs and compress margins, increasing earnings volatility. The bear case factors include potential valuation downside if margins thin; the bull case rests on continued earnings momentum. Read the full narrative to understand the risks, rewards, and what a fresh investor view might look like.
European markets set for flat open as traders await central bank decisions
December 17, 2025, 1:56 AM EST. European stocks look set for a broadly flat start on Wednesday as investors await a slate of central bank decisions. The FTSE, DAX, and CAC 40 hover near flat as Italy's FTSE MIB slips slightly. Markets focus on the ECB's final policy meeting of the year, with rates expected to stay at 2% but Lagarde signaling higher euro-zone growth forecasts. The BoE, Riksbank, and Norges Bank also publish policy decisions this week. The BOE is seen delivering a 25 basis-point cut to 3.75% amid softer growth and possible upticks in unemployment, while November inflation is expected at 3.5% from 3.6% in October. U.S. futures fell after a mixed jobs report, and Asia-Pacific traded mixed.
SATS Ltd Stock (SGX: S58) Rallies on Buybacks, WFS Deal, and Bullish Broker Targets
December 17, 2025, 1:54 AM EST. SATS Ltd (SGX: S58) traded around S$3.72-S$3.73 on 17 December 2025 as investors digest three catalysts: an ongoing share buyback programme, renewed WFS cargo handling momentum through its Saudia Cargo deal, and a wave of broker targets that sit above the current level. By mid-session, the stock was up about 2% and near the top end of its range, with a weekly gain of roughly 8.8%. The buyback update shows cumulative purchases of 6.56 million shares since inception, reinforcing management's confidence in earnings power. The WFS contract renewal across eight major gateways in Europe and the United States underpins near-term operating momentum for the SATS group.
ASX 200 Dips Again as Droneshield Loses Momentum; GrainCorp and DRO Lead Declines, IGO and Liontown Rally
December 17, 2025, 1:53 AM EST. Australian shares extended their decline on Wednesday, with the S&P/ASX 200 down 0.16% to 8,585.20 and slipping below the 20-day moving average. GrainCorp Limited and DroneShield Limited (DRO) were the session's bottom performers, down 14.92% and 11.92%, as DroneShield lost momentum after Tuesday's surge. Despite the softer broad move, several names advanced: IGO Limited (IGO) led gains, up about 12.4% to $7.69, followed by Liontown Limited (LTR), Catalyst Metals Limited (CYL), Deep Yellow Limited (DYL), and Westgold Resources Limited (WGX). Over the last five days the index has been largely flat, but is about 5.22% higher over the last year. Tuesday's session had the ASX 200 retreat 0.42% to 8,598.90.
Gecina (OTCMKTS:GECFF) Stock Drops 0.1% as Analyst Ratings Vary
December 17, 2025, 1:47 AM EST. Gecina, trading as OTCMKTS:GECFF, slid 0.1% to $92.45 on Tuesday amid light volume (53 shares). The session followed a close of $92.50. Analysts offer mixed signals: Citigroup upgraded to Strong Buy, while Barclays cut to Hold, BNP Paribas to Neutral, and Goldman Sachs lifted to Buy. The consensus sits at Moderate Buy per MarketBeat, with one Strong Buy, one Buy, and two Holds reported. The stock sits below its 50-day moving average of $94.29 and well under the 200-day MA of $99.94. Gecina is a Paris-region real estate specialist owning, managing, and developing central office and housing space, spanning over 1.2 million sq m and 9,000 units. This note reflects ongoing analyst reevaluations and market sentiment.
Gecina Stock Dips 0.1% as Analysts Split on Ratings (GECFF)
December 17, 2025, 1:46 AM EST. Gecina (OTCMKTS:GECFF) edged down 0.1% on Tuesday, trading as low as $92.45 and closing near that level. Only 53 shares changed hands, well below the average volume. Analysts remain mixed: Citigroup upgraded from strong sell to strong buy, while Barclays and BNP Paribas trimmed calls to hold/neutral, and Goldman Sachs lifted to a buy. MarketBeat's consensus sits at a Moderate Buy with 1 Strong Buy, 1 Buy and 2 Holds. The stock sits near its 50-day moving average of $94.29, below the 200-day moving average of $99.94. Gecina focuses on centrality and sustainable living spaces in the Paris region, owning and developing offices and housing. Investors will want to watch upcoming analyst commentary and moving-average signals for direction.
Australian Shares Flat as US Jobs Data Keeps Rate-Cut Bets Alive; Credit Corp Bids for Humm, TWE Falls, Santos Sells Stake
December 17, 2025, 1:46 AM EST. Australian shares finished broadly flat, with the S&P/ASX 200 near 8,585 as investors weighed a stronger US jobs report against a hawkish local backdrop. US nonfarm payrolls rose 64,000 and the unemployment rate ticked to 4.6%, keeping near-term rate-cut bets alive but modest, with Bloomberg citing about a 20% chance of a January cut. Locally, Westpac/Melbourne Institute data signaled slower momentum and an extended hold on the RBA cash rate into 2026 amid sticky inflation. In company news, Credit Corp Group (ASX: CCP) made a confidential bid to acquire Humm Group (ASX: HUM); both stocks slipped ~3%. Treasury Wine Estates (ASX: TWE) warned for H1 EBITS AU$225m-AU$235m and fell over 9%. Santos (ASX: STO) sold its 42.86% Mahalo stake to Comet Ridge (ASX: COI); STO slipped while COI jumped ~14%.
Australian Shares Flat as US Jobs Data Keeps Rate-Cut Bets; Credit Corp Proposes to Buy Humm
December 17, 2025, 1:44 AM EST. Australian shares finished flat, with the ASX 200 around 8,585 as US payrolls data kept traders cautious on near-term rate-cut bets. Nonfarm payrolls rose 64,000 and the unemployment rate held at 4.6%, reinforcing a softer labor market and keeping a roughly 20% chance of a January cut. Domestically, Westpac/Melbourne Institute data showed November activity cooling, supporting a 2026 RBA hold outlook. In company news, Credit Corp Group (CCP) filed a confidential bid to acquire Humm Group (HUM); both stocks fell about 3%. Treasury Wine Estates (TWE) warned H1 EBITS of AU$225-235m and dropped over 9%, while Santos (STO) agreed to sell its Mahalo stake to Comet Ridge (COI); STO slid about 1%, COI rose around 14%.
OCBC Stock Outlook (SGX: O39): Near-Term Valuation Question, Dividends and 2025 Strategy Headlines
December 17, 2025, 1:43 AM EST. OCBC (SGX: O39) sits near the top of its annual range as investors weigh a steadier earnings path against a fading rate tailwind. On Dec 17, 2025 the stock traded about S$19.3-19.4, near a 52-week high of S$19.47, with a daily move of around -0.4%. The debate centers on whether valuations are fully priced or will rerate on stronger fee income, wealth-management, and capital returns. The bank's upside hinges on dividends and share buybacks, plus longer-term catalysts from its strategic push into ecosystems. Key 2025 headlines include Marriott supplier financing to speed SME working capital, and plans to expand China QR payments, aiming to lift transaction volumes and digital deposits. If margins stabilize and the optionality from fee businesses materializes, OCBC could extend its performance.
ASX 200 Dips Further as Droneshield Slips; Top Gainers and Losers on Dec 17, 2025
December 17, 2025, 1:40 AM EST. Australian shares extended the downturn on Wednesday, with the S&P/ASX 200 slipping 13.70 points (0.16%) to 8,585.20 and breaching its 20-day moving average. The day's worst performers included GrainCorp (GNC) and DroneShield (DRO), down 14.92% and 11.92% respectively. DroneShield had surged the previous session, but momentum faded a day after topping the index's gainers, with a closing at $2.81 on Tuesday. Over the past five sessions the index was largely flat, though the year-to-date return remains positive at about 5.2%. In the top losers, Austal (ASB) and Telix (TLX) also fell, while IGO, Liontown, CYL, DYL, and WGX led the gains.
DBS Group Holdings Ltd Stock (SGX: D05) poised for RMB clearing expansion and cross-border payments growth as 2025 winds down
December 17, 2025, 1:39 AM EST. DBS Group Holdings Ltd (SGX: D05) closes 17 December 2025 near 52-week highs, trading around S$55.05 after a run that tests how a high-quality bank can sustain returns as rate tailwinds fade. The key catalyst is strategic: DBS became Singapore's second RMB clearing bank, with approvals to clear and access China's onshore OTC RMB bond market, expanding cross-border settlement, FX, and RMB capital markets services. These developments, announced amid MAS cooperation and broader Singapore-China financial ties, aim to feed fee and transaction income through payments, liquidity, custody, and infrastructure roles. Separately, a digital RMB wallet pilot for travellers hints at broader RMB usage. The stock's next test is whether offline-margin resilience and capital returns can be supported by RMB-related rails in a lower-rate environment.
DBS Group Holdings Ltd (SGX: D05) Latest News: RMB Clearing Bank Appointment, Cross-Border Growth, and Dividend Outlook (Dec 17, 2025)
December 17, 2025, 1:38 AM EST. DBS Group Holdings took a strategic leap by being named Singapore's second RMB clearing bank and gaining access to China's onshore OTC bond market, deepening its cross-border settlement capabilities. The December 15, 2025 moves position DBS to capitalize on growing offshore RMB activity and broader RMB infrastructure, potentially boosting transactions, FX, custody, and capital-markets fees. In a low-rate world, net interest margin pressure persists, so DBS investors will look for a sustainable dividend outlook and evidence that the bank can grow fee-based income without compromising risk standards. Singapore's MAS framed the collaboration as a catalyst for corporates, and DBS' strategy as expanding its role in the regional payments ecosystem amid a higher competition landscape.
CDL Stock Gains as Quayside Isle Sale Amplifies Capital Recycling and Value-Unlocking Theme
December 17, 2025, 1:37 AM EST. CDL shares edged higher on Dec 17 as the group advances a capital-recycling play that investors increasingly view as a value-unlocking story. At 1:51pm SGT, City Developments (CDL) traded at S$7.61, up 1.47%. The centerpiece was the divestment of Quayside Isle at Sentosa Cove for S$97.3 million, roughly a 47% premium to book value and a 2.6% cap rate, with completion targeted for Q1 2026. Management frames this as part of an ongoing asset recycling and portfolio optimisation push designed to lift debt resilience, enhance distributions, and fund new development. 2025 has already seen major disposals – including South Beach (with IOI) and the proposed Bespoke Hotel Osaka Shinsaibashi sale to Blackstone-managed funds, plus the Sunnyvale residential divestment – underscoring CDL's strategy to rebalance assets and improve value versus a lingering discount to asset value.
CDL Stock in Focus: Quayside Isle Sale, 2025 Asset Recycling, and What Could Move CDL Shares Next (Dec 17, 2025)
December 17, 2025, 1:35 AM EST. City Developments Limited (CDL) shares rose as investors priced in fresh monetisation headlines and a line of broker commentary framing CDL as a value-unlocking story. The stock traded around S$7.61 at 1:51pm SGT, up 1.47%. CDL announced the sale of Quayside Isle at Sentosa Cove for S$97.3 million, about a 47% premium to book value, and a 2.6% cap rate, with completion expected in Q1 2026. This marks the eighth asset divestment in 2025 as CDL pursues capital recycling, selective reinvestment, and balance-sheet strengthening. Earlier moves include South Beach disposal for a premium to valuation and a Osaka Bespoke Hotel sale to Blackstone funds, plus Sunnyvale residential divestment. The theme: scale asset recycling to unlock value, de-leverage, and potentially lift distributions.
Singtel Stock (SGX: Z74) Today: Dividend Outlook, Regulatory Focus, and Analyst Forecasts as of Dec 17, 2025
December 17, 2025, 1:34 AM EST.SingTel (SGX: Z74) trades near S$4.54 on Dec 17, 2025, with a ~4% dividend yield and a trailing P/E around 12. The stock sits in a story of resilient cash flows and shareholder returns, offset by regulatory and operational risk centred on Optus. Investors are weighing SingTel's multi-year capital-return cycle and portfolio reshaping toward faster-growth units like Nxera and NCS. Key risk updates include an IMDA S$1 million penalty for a 2024 landline disruption, underscoring that network resilience is a regulatory and reputation issue, and ongoing Optus service incidents affecting costs and brand trust. Analyst targets and the next leg up depend on capex pacing, divestments, and growth in data-centre/digital infra.
Singtel Stock Today: Dividend Outlook, Capital Returns, and Risks (Dec 17, 2025)
December 17, 2025, 1:33 AM EST. Singtel trades near S$4.54 on Dec 17, 2025, near the upper end of its 12-month range as investors weigh steady cash flow and renewed capital returns against regulatory and execution risks. Key stats: ~S$4.54 price, 52-week range ~S$3.04-S$4.92, market cap ~S$74.6B, dividend yield ~4%, P/E ~12x. The stock is in a multi-year cycle of capital returns and portfolio reshaping while growing units like Nxera and NCS. Regulatory headwinds include IMDA's S$1 million penalty for the 2024 landline disruption, highlighting resilience as a non-financial risk. Optus remains the main risk factor, with outages drawing scrutiny and potential impact on serviceability and costs. Analysts' targets and the next catalysts (divestments, buybacks, capex shift) will shape the next leg for Singtel.
Nephrocare Health IPO debuts with 6.9% premium; strong demand and 13.96x subscription
December 17, 2025, 1:17 AM EST.Nephrocare Health priced its IPO at ₹460 and listed with a 6.89% premium, opening at ₹490-₹491 on NSE/BSE. Listing day trade was modest after a grey-market premium around ₹37. The book-built IPO size was about ₹871 crore, combining a fresh issue and an offer-for-sale, with a price band of ₹438-460 and a lot size of 32 shares. The issue was subscribed 13.96x, led by QIBs (27.47x), followed by NII (24.27x) and retail (2.31x). Proceeds are to expand its dialysis clinic network, pare debt, and meet general corporate needs. Nephrocare Health operates dialysis and renal-care clinics across Tier-2/3 cities, with an asset-light model and footprint in select international markets.
Nasdaq pushes for 23-hour trading as markets eye 24/7 cycle
December 17, 2025, 1:16 AM EST. Nasdaq has asked regulators to allow a 23-hour weekday trading session, extending from the current 9:30am-4pm ET window. Starting in Q3 2026, the exchange would open from 9pm to 4am, aiming to serve global investors and insomniacs who want to react to overnight news. The plan has drawn skepticism on Wall Street: critics warn that near-constant trading could reduce time to digest earnings and other disclosures, potentially boosting volatility and lowering liquidity. Wells Fargo's desk even called the proposal 'the worst thing in the world' for turning stocks into more of a gamble. Competitors aren't waiting: the NYSE is weighing a 22-hour day, and platforms like Robinhood already offer night trading, illustrating the race to 24/7 markets.
PLS Group Limited (ASX:PLS) Rises on Lithium Rally as JPMorgan Lifts Target to A$4.80
December 17, 2025, 1:14 AM EST. SYDNEY – 17 December 2025: PLS Group Limited (ASX: PLS) shares jumped about 5% to around A$4.08, keeping it near its 52-week high of A$4.20 as the lithium rally extended. The advance tracked broader strength in battery materials, with Liontown and Mineral Resources also higher. Analysts cited stronger demand for electric vehicles (EVs) and battery energy storage systems (BESS). Morgan Stanley highlighted rising China BEV demand and a year-to-date lift, while UBS forecast steady EV output and growing BESS demand. Market Index flagged PLS among top gainers in lithium. Notably, JPMorgan lifted the target to A$4.80 from A$3.60, supporting the bullish tone. Traders watch if optimism endures amid broker updates and company news.
Markets Trade Flat In Early Deals Amid Weak Global Cues; Sensex Opens 176 Points Higher
December 17, 2025, 1:04 AM EST. Indian equities opened higher on a flat-to-positive note but pared gains soon, with the Sensex nudging higher by 176 points to 84,856 before slipping to 84,649. By 9:25 AM, the Nifty hovered around 25,913, up about 0.2%. Banking stocks showed a mixed bag: SBI, Bajaj Finance, Axis Bank among gainers (~1%), while ICICI Bank and HDFC Bank lagged. The broader market stayed muted, with the BSE MidCap up ~0.1% and SmallCap down ~0.1%. The rupee opened at 91.07 per dollar. Overseas, Asian markets edged higher; in the US, the S&P 500 slipped 0.24%, Nasdaq rose 0.23%, and Dow fell 0.62%. FIIs were net sellers worth Rs 2,060.76 crore, while DIIs supported with net buys of Rs 770.76 crore.
Sensex, Nifty Open Higher as PSU Banks Rally; Rupee Hits Record Low
December 17, 2025, 1:03 AM EST. Benchmark indices opened marginally higher as the rupee touched a record low, with PSU banks providing support in early trade. The Sensex rose 91.32 points to 84,771.18, while the Nifty50 added 44.40 points to 25,904.50 at 9:22 am. Among the top performers were Eternal, State Bank of India, TVS Motor Company, Bajaj Finance and Axis Bank. The downside remained visible in ICICI Bank, Trent, HDFC Bank, Sun Pharma and Kotak Mahindra Bank. Analysts say the fall in crude and the rupee's depreciation are shaping flows, even as some expect a 2026 rally if FIIs swing back and a possible US-India trade deal materializes. Market watchers warn on persistent rupee weakness and policy cues.
Brambles Limited (ASX: BXB) Buy-Back Progress, New Share Quotations, and Analyst Forecasts – 17 December 2025 Update
December 17, 2025, 1:00 AM EST. Brambles Limited (ASX: BXB) released a market-facing update on 17 December 2025, signaling steady execution of its FY26 on-market buy-back and two small tranches of ordinary shares for employee incentive plans. The daily update (Appendix 3C) shows 16 December purchases of 301,596 shares for about A$6.86 million, with an implied average price near A$22.76 and a 16 December intraday range of A$22.63-A$23.02. Cumulatively, Brambles has bought back 11,181,992 shares before 16 December, rising to 11,483,588 shares for around A$278.33 million disclosed to date. Brambles traded around A$22.78 on 17 December, within a 52-week band of A$18.65-A$26.93. Together, the updates reinforce a narrative of capital returns via buy-backs and modest equity issuance, amid questions about valuation as a quality compounder vs. expensive defensive.
Rio2 Limited (TSX:RIO) Stock Surges 4.1%
December 17, 2025, 12:59 AM EST. Rio2 Limited (TSX:RIO) rose 4.1% on Tuesday, trading as high as C$2.85 and closing near C$2.80. Volume reached 2,194,752 shares, about 384% above the average of 453,570. The company shows a debt-to-equity ratio of 0.44, a current ratio of 17.39, and a quick ratio of 1.10. Its 50-day SMA is C$2.16, while the 200-day SMA stands at C$1.80. Rio2's market capitalization is around C$1.20 billion, with a P/E ratio of -26.35 and a beta of 1.57. The Vancouver-based miner operates in Canada, Peru, the Bahamas and Chile, including the 100% Fenix Gold Project in Chile.
West Pharmaceutical Services (WST) Valuation Reassessment After a ~20% Pullback
December 17, 2025, 12:58 AM EST. West Pharmaceutical Services (WST) has fallen ~20% over the past year even as revenue and net income climb, prompting a fresh look at valuation. The narrative argues momentum has cooled and asks if the stock is undervalued or if the market has priced in slower growth. The bull case rests on higher-margin HVP components, a favorable mix shift, and a ramp in Annex 1 projects, plus a strategic push into higher-margin contract manufacturing with drug handling. The model sets a fair value near $346.07, implying about 23% upside, though the shares trade at roughly 39x earnings vs. a Life Sciences sector ~36x and a fair ~25x. Risks include softer demand for high-value components and execution missteps. Bottom line: validate the earnings build and whether the premium multiple is justified.
Nordic Fibreboard: Rosamil OÜ acquires 48.33% stake from Väätä Agro AS; Joakim Helenius remains ultimate owner
December 17, 2025, 12:50 AM EST.Nordic Fibreboard AS filed a change in significant holding under §186 of the Securities Market Act. On 10.12.2025, VÄÄTSA AGRO AS sold 4,107,240 shares (48.33%) to ROSAMIL OÜ. Post-transaction, VÄÄTSA AGRO AS holds 0 shares while ROSAMIL OÜ holds 4,107,240 shares (48.33%). Joakim Johan Helenius, who directly and indirectly controls both entities, still owns 81.37% of Nordic Fibreboard AS. The move is an intra-related-party transfer with no change in ultimate control. For investor inquiries, contact Nordic Fibreboard's management at group@nordicfibreboard.com.
Phillips 66 (PSX) Valuation Check: Is the Pullback Undervalued?
December 17, 2025, 12:48 AM EST. Phillips 66 (PSX) has cooled after a strong run, down about 7% in the last month while remaining positive YTD. At approximately $131.78, the stock's momentum softened, but longer-term returns and a history of resilient TSR point to a durable story. The article argues PSX could be undervalued, citing a narrative fair value around $268.71 and shares trading well below that level, yet warns that revenue growth has slowed and profitability depends on favorable refining margins. It notes PSX trades about 35.5x earnings versus an industry average near 13.2x and a market-wide fair multiple of ~24.7x, implying the market has already baked in much good news. Investors face a balance: potential upside if the narrative holds, but risk if margins disappoint and the multiple compresses.
Parker-Hannifin (PH) Valuation After a Multi-Year Share Price Surge
December 17, 2025, 12:45 AM EST. PH has rallied into a multi-year compounder, with shares up around 18% in 3 months and over 30% in the past year. The stock sits near $874.49 while the fair value estimate has ticked higher to $907.86, suggesting the name remains modestly undervalued after a durable run. Five key signals: a 3-year TSR of 216.38% confirms sustained momentum; a P/E of 30.3x versus the US Machinery average of 25.6x hints at premium demand for execution; a narrative built on steady revenue growth, resilient margins, and a richer future profit multiple; but risks include a cyclical industrial recovery and integration risk from acquisitions. Investors should test the thesis against their own assumptions.
Jardine Cycle & Carriage (SGX:C07) Delivers 115% Five-Year TSR Driven by Dividends
December 17, 2025, 12:44 AM EST. Stock pickers seek above-market gains; Jardine Cycle & Carriage delivered a five-year total shareholder return (TSR) of 115%, helped by dividends that widened the gap with price gains. The share price rose about 71% over five years, beating the ~39% market rise, while earnings per share grew a modest 2.0% per year-far below the roughly 11% annual rise in the share price, signaling strong investor sentiment. Insiders have been buying in the last 12 months, a potentially bullish signal. Looking ahead, investors should weigh future earnings against the dividend contribution, since the next leg will depend on whether earnings can sustain or accelerate to justify the current multiple.
Park Medi World IPO Debuts Below ₹162 on BSE/NSE Despite Strong Subscription; GMP Signals and Listing Day Snapshot
December 17, 2025, 12:43 AM EST. On 17 December 2025, the Park Medi World IPO priced at ₹162 and listed below that level on both BSE and NSE. The stock opened at ₹155.60 on BSE (−3.95%) and ₹158.80 on NSE (−1.98%), winding up the session modestly lower despite an oversubscribed issue (8x+). The muted debut came despite strong feedback from NIIs and QIBs and days of grey market chatter that hinted at a small premium. Pre-listing GMP had drifted lower, signaling modest listing gains. Initial trading suggested some bargain-hunting, with a partial recovery from the day's lows. Moneycontrol pegged the debut market cap near ₹6,721 crore. Analysts flagged valuation versus peers and higher leverage, and noted a crowded IPO calendar affecting retail participation.
UK markets 2025: Growth stalls, BoE rate cuts disappoint, two-speed equity story
December 17, 2025, 12:43 AM EST. 2025 proved volatile for Britain: the Bank of England didn't cut rates as far as expected as inflation stayed stubborn. Consumers remained under pressure, weighing on stocks even as the FTSE 100 outperformed the domestically focused FTSE 250. GDP rose modestly early in the year but weakest quarters followed, with Q2-Q3 growth fading and the economy contracting in September and October. The jobs market echoed the slowdown, with unemployment ticking up to 5.1%. Other drivers included a cyber-attack on Jaguar Land Rover, a tepid housing market, and tariff talk around the U.S. with some inventory rebuilding by exporters. The takeaway: a two-speed UK market with a fragile domestic demand backdrop.
Foran Mining Corp. (FOM:CA) Target Raised; Analysts Turn Constructive
December 17, 2025, 12:33 AM EST. Ventum Financial raised Foran Mining Corp.'s 12-month target to $5.50 from $5.25, citing an improved risk-reward profile and progress toward development milestones. The upgrade underscores the stock's exposure to copper and zinc, with demand supported by electrification, infrastructure investment, and the energy transition. Ongoing advancement at key projects, along with closer-to-de-risked permitting and engineering milestones, could lift long-term value and production timelines. Technically, shares show a Strong Buy signal, while fundamentals carry a Buy rating from analysts. The average 12-month target sits near $5.15, implying roughly 19% upside. Together, momentum, improving fundamentals, and potential valuation expansion keep Foran well positioned if execution remains on track; disclosure acknowledged as syndicated content.
Foran Mining Corp. (FOM:CA) Analyst Update Signals Constructive Upside as Copper & Zinc Demand Strengthen
December 17, 2025, 12:32 AM EST. Foran Mining Corp. (FOM:CA) received an analyst upgrade as Ventum Financial lifted its 12-month target to $5.50 from $5.25, citing an improved risk-reward profile and progress on development milestones. The note emphasizes exposure to copper and zinc amid stronger electrification and the global energy transition, with advancing permitting, engineering, and de-risking of key projects supporting higher valuation. While the target implies upside, the broader consensus shows an average 12-month target near $5.15, signaling more modest upside depending on execution and commodity prices. Technically, the name displays momentum and a Strong Buy signal, reinforced by a Buy rating from analysts and potential for multiple expansion if execution remains on track.
Three Asian Stocks Trading Up to 41.9% Below Intrinsic Value; Eyebright Medical Tech Leads the Region
December 17, 2025, 12:31 AM EST. Asian markets show promising gaps where stocks trade well below their intrinsic value based on cash-flow valuations. The screener shows discounts around the 48-50% range for names like Xiamen Amoytop Biotech, Wuhan Guide Infrared, Wacom, Sany Heavy Equipment, KIYO Learning, Ibiden, Global Security Experts, Daiichi Sankyo, Cowell e Holdings, and Andes Technology. Notably, Eyebright Medical Technology (Beijing) stands out with a 41.9% discount to its fair value, trading at CN¥62.08 vs CN¥106.87 estimated fair value, reflecting enduring undervaluation despite earnings growth around 22.4% and revenue expansion. The list also features APR Co., Ltd.'s cosmetics operations with a 24.6% discount. Investors seek cash-flow-backed undervaluations as catalysts for potential upside in the coming years.
Asian Stocks Trading Below Intrinsic Value: Notable Picks With Up To 41.9% Discount
December 17, 2025, 12:30 AM EST. Amid rate moves and shifting data, Asian stocks present value opportunities for investors seeking bargains. The piece spotlights names trading well below intrinsic value, underpinned by cash flows and improving fundamentals. Notable screens show discounts near 48-50% to fair value for several names, including Xiamen Amoytop Biotech, Wuhan Guide Infrared, Sany Heavy Equipment, KIYO Learning, Ibiden, Global Security Experts, Daiichi Sankyo, Cowell e Holdings and Andes Technology. A highlighted pair includes Eyebright Medical Technology with a 41.9% discount to a CN¥106.87 fair value, despite mixed near-term earnings. Another example, APR Co. (APR Corp.), trades below fair value with expected earnings growth, though dividend coverage by free cash flow is cautious. The message: discounted cash flow screens can flag undervalued plays in a volatile region.
India equities muted amid uncertain Fed outlook; FP selling weighs on rupee
December 17, 2025, 12:28 AM EST. India's benchmarks in subdued trade as mixed U.S. jobs data keeps Fed rate path uncertain. The Nifty 50 and Sensex rose about 0.1% in early trade, with roughly 10 of 16 sectors advancing. Mid- and small-cap indices held broadly steady. Asian markets were muted as investors await U.S. CPI data after November jobs data showed payroll gains but a rising unemployment rate of 4.6%. Higher U.S. rates weigh on EM flows, contributing to eight straight sessions of foreign selling and a softer rupee. Traders eye the India-U.S. trade talks for clarity. Stock news: Shriram Finance jumped 2.2% ahead of its December 19 board meeting to raise funds, while Indian Overseas Bank slumped 3.5% after an offer-for-sale of up to 3% stake.
India equities muted as Fed outlook and FPI selling weigh on benchmarks
December 17, 2025, 12:27 AM EST. India's benchmarks nudged higher in thin early trade, with Nifty 50 and Sensex up about 0.1% to 25,881.7 and 84,719.84 as traders awaited cues from the U.S. outlook. Asian peers were muted as mixed U.S. jobs data kept the Fed trajectory uncertain. November jobs rose more than expected, but the unemployment rate climbed to 4.6%, keeping investors focused on the upcoming U.S. CPI print. Elevated U.S. rates keep foreign portfolio investors (FPIs) wary of entering EMs, and inflows have persisted in selling for eight sessions, pressuring the rupee. Local names saw mixed moves; Shriram Finance rose 2.2% ahead of a December 19 board meeting to discuss fund-raising, while Indian Overseas Bank slid 3.5% after the government offered up to a 3% stake sale at a floor of ₹34.
Is Charles River Laboratories Stock Undervalued After 2025 Rebound?
December 17, 2025, 12:25 AM EST. Charles River Laboratories International has attracted attention as investors weigh whether the stock is undervalued after a 2025 price rebound. The shares have shown momentum, rising about 5% in the last week and 16% in the last month, even as longer-term returns remain mixed. Market dynamics (regulatory updates, contract wins in preclinical and biologics, and scrutiny of animal research) shape sentiment on its growth runway. With a valuation score of 5/6, the stock looks attractive on several metrics, while a Discounted Cash Flow analysis points to an intrinsic value around $258.60 per share, implying a ~24.5% discount to today's price. If cash flows skew with investment cycles, a traditional P/S lens can also help frame reasonable upside.
Nifty50 opens flat; Sensex near 84,700 as markets await catalysts
December 17, 2025, 12:24 AM EST. Stock market today: Nifty50 opened flat around 25,864 and the Sensex hovered near 84,700, with both indices showing marginal moves in early trade. Market experts expect a sideways session due to a lack of near-term catalysts. Dr. VK Vijayakumar notes rupee weakness and softer crude as macro positives, but sustained depreciation could fuel FIIs outflows, while a tame November CPI (0.71%) supports imported inflation risk being limited. The backdrop saw US markets mixed (Nasdaq higher; S&P 500 and Dow lower) and oil prices rising after Trump's embargo on Venezuelan crude tankers. FPIs were net sellers (Rs 2,381 crore) amid net buys by DIIs (Rs 1,077 crore). The piece hints at a possible 2026 rally if FIIs turn buyers on a US-India trade deal, with rupee strength possible in H1 2026.
Stock Market Today: Nifty50 Flat, Sensex Near 84,700 as Sideways Trading Looms
December 17, 2025, 12:23 AM EST. Indian benchmarks opened flat with Nifty50 around 25,864 and Sensex near 84,705. Traders expect sideways trading amid a dearth of short-term catalysts. Geojit's Dr. VK Vijayakumar notes rupee weakness and crude moves as key macro drivers; a sharper fall in the rupee could dampen flows even as lower inflation supports the economy. With CPI at 0.71% in November, imported inflation remains contained, and RBI policy stance is pivotal. The outlook suggests FIIs may turn buyers in 2026 if a broader US-India trade deal and other catalysts emerge, possibly lifting sentiment into a 2026 rally. Globally, US indices were mixed, oil rose on Venezuela embargo news, and FPIs sold about ₹2,381 crore while DIIs bought ₹1,077 crore.
Nephrocare Health share price: Stock lists at 6.5% premium on NSE; here's how much investors made per lot
December 17, 2025, 12:22 AM EST. This note primarily covers broker registrations, compliance contacts, and investor risk disclosures rather than Nephrocare Health price data. It lists Upstox Securities and RKSV Commodities details, including SEBI registrations, NSE/BSE/MCX codes, and compliance officers. It explains how to file complaints on the SEBI SCORES portal and outlines the information required for lodging grievances. The document also emphasizes risk disclosures for derivatives, noting high net trading losses among individual traders and the associated transaction costs. It warns that these are not exchange-traded products and that disputes fall outside the Exchange investor redressal forum for distribution activities. Finally, it cites NSE/BSE/MCX circular cautions against unauthorised schemes and reminders to read Risk Disclosure Documents and Privacy/Terms. Investors should seek official stock data from reliable platforms for prices and per-lot calculations.
Nephrocare Health stock lists at 6.5% premium on NSE; investors weigh per-lot gains
December 17, 2025, 12:21 AM EST. Nephrocare Health Ltd. debuted on the NSE with a listed price at about a 6.5% premium to the issue price, signaling strong early demand. The story promises to show how much investors made per lot, but the excerpt does not include the exact per-lot gains. Also included are broker disclosures from Upstox/RKSV affiliates and SEBI registration details, along with complaint channels. Readers are cautioned about market risks and the costs associated with derivatives, and urged to review risk disclosures and policy documents before investing. Takeaways: monitor the final listing trades on NSE, compare with the offer price, and consider broker charges and regulatory disclosures when assessing listing gains.
Nifty50 opens flat; Sensex near 84,700 as markets stay cautious
December 17, 2025, 12:20 AM EST. Markets opened flat with Nifty50 around 25,864 and the Sensex near 84,700, signaling a cautious, sideways session in the absence of major catalysts. At 9:16 AM, Nifty50 traded at 25,864.25 and Sensex at 84,705.43. Dr. VK Vijayakumar notes that a weaker rupee and softer crude support India's macro story, even as depreciation risks FII outflows. He sees potential FIIs turning buyers in 2026 if a US-India trade deal emerges, potentially lifting the rupee in H1 2026. Globally, US indices were mixed and oil rose after news of Venezuela embargo. Foreign investors sold Rs 2,381 crore, while domestic institutions bought Rs 1,077 crore yesterday. Investors remain cautious but watchful for a mid-term rally.
Workday Valuation Reassessed: Earnings Beat, Sharp Selloff, and a Path to Fair Value
December 17, 2025, 12:19 AM EST. Workday (WDAY) beat quarterly revenue and earnings estimates, yet the stock sold off as investors fixated on slower core growth and pricey AI bets. Year-to-date shares are down ~14% and 1-year total return ~-22%, vs a 3-year total return of ~+26%, signaling fading momentum. The central question: is WDAY undervalued at a last close of $216.11 with a fair value near $275.64, or does the market rightly price in slower gains? The bull case rests on expansion into new product lines like Workday GO and verticals (financial management, government) to lift revenue growth and margins, supported by a growing backlog. Risks include AI competition and heavy R&D/M&A spending that could erode profitability. The verdict hinges on the multiple versus peers.
Workday Valuation Reassessed After Earnings Beat and Sharp Sell-Off
December 17, 2025, 12:18 AM EST. Workday (WDAY) delivered a quarterly beat on revenue and earnings, but the stock sold off as investors flagged slower core growth and concerns about high AI-related spending. Our analysis notes a broader cooling trend: YTD return of -14.19% and 1-year TSR of -22.27% contrast with a +25.58% 3-year TSR, signaling fading momentum and a debate over how much investors should pay for growth. With shares near $216 vs. a narrative fair value around $275, the valuation case appears positive only if durable growth, widening margins and expanding TAM through products like Workday GO and verticals like financial management and government can sustain a premium. Key risks include intensifying AI competition, heavy R&D/M&A spend, and potential multiple contraction.
Nephrocare Health share price: NSE lists stock at 6.5% premium; here's how much investors made per lot
December 17, 2025, 12:17 AM EST. Nephrocare Health's shares listed on the NSE at a 6.5% premium to the issue price. This piece explains how much investors made per lot, outlining how outcome depends on lot size, listing price, and intraday moves. It notes that transaction costs and broker commissions can trim gains, and reminds readers that equities carry risk and require thorough reading of offer documents and risk disclosures. The report also references issuer disclosures and standard compliance notes from brokers such as Upstox and RKSV, along with investor cautions about unauthorised schemes.
Reassessing Workday Valuation After Earnings Beat and Sharp Post-Results Selloff
December 17, 2025, 12:16 AM EST. Workday (WDAY) beat revenue and earnings while the stock fell sharply, as investors priced in slower core growth and questions about expensive AI bets. The pullback fits a broader cooling trend: YTD return -14.19%, 1-year -22.27%, but a 3-year TSR of +25.58%. The debate now centers on whether WDAY is undervalued or fairly priced for slower future gains. With shares near $216 vs a fair value near $275.64, the bull case rests on durable growth and margin expansion, aided by new offerings like Workday GO and verticals in financial management and federal government. Risks include intensifying AI competition and heavy R&D/M&A spend that could compress profitability. The multiple (about 88.5x earnings) versus peers highlights the momentum trap vs patient entry.
Is Charles River Laboratories Stock Attractively Priced After the 2025 Rebound?
December 17, 2025, 12:15 AM EST. Charles River Laboratories International appears potentially undervalued after a 2025 rebound. The stock has shown momentum with gains over the past week and month, even as longer-term returns lag. A 5/6 valuation score suggests the shares look undervalued on several metrics. A two-stage DCF model pegs the intrinsic value around $258.60 per share, implying roughly a 24.5% discount to the current price if forecasts prove correct. The model bases its case on roughly $497 million in trailing free cash flow, with a path to about $893 million by 2035 as growth matures. The analysis also highlights how demand for outsourced drug discovery could support repeatable earnings, though regulatory and animal-research scrutiny shapes sentiment. Investors should weigh near-term volatility against the longer growth runway and cash-flow quality.
Is Charles River Laboratories Stock Attractively Priced After 2025 Rebound?
December 17, 2025, 12:12 AM EST. Charles River Laboratories International has gained momentum in 2025, but the question remains whether the stock is truly undervalued. A 5/6 valuation score and a Discounted Cash Flow (DCF) model place the stock at an intrinsic value of about $258.60 per share, implying roughly a 24.5% discount to the current price. The analysis hinges on a two-stage FCF forecast, with a growing, then moderating path as the business scales. With recent contract wins in preclinical and biologics, plus ongoing demand for outsourced drug discovery, the stock could offer meaningful upside if forecasts prove accurate. Still, investors should weigh regulatory headwinds and earnings sensitivity to investment cycles before adding to a watchlist.
Ericsson's 3-Year Surge Sparks Debate Over Long-Term Value
December 17, 2025, 12:11 AM EST. Ericsson (Telefonaktiebolaget LM Ericsson) has seen a 67.6% rise over three years while trading near SEK 89.6, with a flat year-to-date. The piece argues that the real story lies in the longer horizon as the company pushes into 5G and cloud-native networks and tightens partnerships with major operators, even as capex cycles and fierce competition temper upside. A DCF model pegs intrinsic value at roughly SEK 139.35 per share, suggesting the stock is about 35.7% undervalued versus today's price. Analysts forecast free cash flow through mid-decade, then tapering, supporting a longer-run case for upside. In sum, Ericsson looks undervalued on a cash-flow basis, but valuation should be weighed against ongoing industry dynamics and execution on its 5G and cloud strategy.
Ericsson's 3-Year Surge Sparks Value Debate: Is There More Upside Ahead?
December 17, 2025, 12:10 AM EST. Ericsson has logged a 67.6% gain over three years, with a flat YTD and a modest 1-year gain, while 5G and cloud-native network initiatives bolster sentiment. Yet concerns over capex cycles and competitive pressures cap multiple expansion. Our take uses a DCF framework: starting from trailing twelve months free cash flow of about SEK 29.7B, forecasts of SEK 23.2B in 2026 rising to SEK 25.2B in 2027, and a terminal value implying an intrinsic value near SEK 139.35 per share versus the current ~SEK 89.6, pointing to about 35.7% undervaluation. The stock trades through a P/E lens but, more holistically, valuation hinges on long-term demand for 5G and network modernization. Bottom line: undervalued on a cash-flow basis, but watch capex cycles and competitive risk.
Ericsson's 3-Year Surge: Is There Still Long-Term Value Beyond the 67.6% Jump?
December 17, 2025, 12:09 AM EST. Ericsson trades near SEK 89.6, roughly flat YTD with a 1-year gain of 3.3 but a 3-year jump of 67.6. The narrative centers on Ericsson's push into 5G and cloud-native networks and partnerships with carriers, supporting a gradually improved sentiment. Yet ongoing telecom capex cycles and fierce competition keep re-rating modest. Using a two-stage FCFE model with last twelve months FCF of about SEK 29.7 billion, the analysis yields an intrinsic value of around SEK 139.35 per share, implying roughly 35.7% undervalued versus the current price. The piece also notes a PE-based view as a complementary gauge. Conclusion: despite solid long-term momentum, the stock appears undervalued on discounted cash flows, suggesting upside if growth holds.
